<DOC>
	<DOCNO>NCT00911144</DOCNO>
	<brief_summary>The purpose study evaluate reactogenicity , safety immunogenicity booster ( fourth ) dose pneumococcal vaccine GSK1024850A co-administered Hiberix 12-18 month age , child prim vaccine primary study NCT00680914 .</brief_summary>
	<brief_title>Booster Vaccination Study With Pneumococcal Vaccine Children Primed With Same Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>A male female , include , 1218 month age time booster vaccination . Subjects investigator believe parent ( ) / guardian ( ) comply requirement protocol . Subjects receive three dos pneumococcal conjugate vaccine study NCT00680914 . Written inform consent obtain parent ( ) /guardian ( ) child/ward . Healthy subject establish medical history clinical examination enter study . Use investigational nonregistered product ( drug vaccine ) within 30 day precede vaccination , plan use study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior vaccination . Administration immunoglobulins and/or blood product within three month precede vaccination plan administration study period . Administration pneumococcal and/or Hib vaccine since end study NCT00680914 . Planned administration/administration vaccine allow study protocol period start 1 month ( 30 day ) administration booster dose study vaccine ( Visit 1 ) followup visit ( Visit 2 ) exception vaccine include Korean routine immunization give least one week administration study vaccine study end . Any confirmed suspected immunosuppressive immunodeficient condition , base medical history physical examination . History reaction allergic disease likely exacerbate component study vaccine . Known hypersensitivity component study vaccine include anaphylactic reaction follow administration study vaccine . Major congenital defect serious chronic illness . History neurologic disorder seizure . Tympanic axillary/ oral temperature &gt; = 37.5°C rectal temperature &gt; = 38.0°C . A temperature great equal cutoff warrant deferral vaccination pending recovery subject . Acute disease time enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Safety</keyword>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Pneumococcal disease</keyword>
	<keyword>Booster vaccination</keyword>
</DOC>